|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Co-regulatory networks of human serum proteins link genetics to disease.
|
30072576 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Chitinase proteins distinguished ALS from healthy controls (area under the curve (AUC): CHIT1 0.92; CHI3L1 0.80; CHI3L2 0.90), mimics (AUC: CHIT1 0.84; CHI3L1 0.73; CHI3L2 0.88) and, to a lesser extent, PLS (AUC: CHIT 0.73; CHI3L1 0.51; CHI3L2 0.82) but did not outperform pNFH.
|
31123140 |
2019 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Tissue multi arrays of conventional RCC without metastasis at the time of operation from a cohort of 634 patients were analysed by immunohistochemistry for expression of the chitinase 3-like protein 2 (CHI3L2).
|
31810965 |
2019 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
In multivariate analysis, the CHI3L2 positivity associated with a 3.5 times higher risk for tumor relapse (p<0.001).
|
31810965 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest YKL-39 as a novel therapeutic target, and blocking of its activity can be combined with NAC in order to reduce the risk of metastasis in breast cancer patients.
|
29872578 |
2018 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, we showed that in patients with breast cancer who received anthracycline-containing NAC the absence of clinical response is associated with the presence of M2+ macrophage phenotype (YKL-39-CCL18 + or YKL-39 + CCL18-) based on TOP2a overexpression data.
|
29728799 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Our findings suggest YKL-39 as a novel therapeutic target, and blocking of its activity can be combined with NAC in order to reduce the risk of metastasis in breast cancer patients.
|
29872578 |
2018 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Tumor-associated macrophages in human breast cancer produce new monocyte attracting and pro-angiogenic factor YKL-39 indicative for increased metastasis after neoadjuvant chemotherapy.
|
29872578 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, we showed that in patients with breast cancer who received anthracycline-containing NAC the absence of clinical response is associated with the presence of M2+ macrophage phenotype (YKL-39-CCL18 + or YKL-39 + CCL18-) based on TOP2a overexpression data.
|
29728799 |
2018 |
|
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our findings suggest YKL-39 as a novel therapeutic target, and blocking of its activity can be combined with NAC in order to reduce the risk of metastasis in breast cancer patients.
|
29872578 |
2018 |
|
Amyotrophic Lateral Sclerosis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
We showed that CHI3L1 and CHI3L2 were significantly upregulated in sALS smokers compared to non-smokers.
|
28989002 |
2017 |
|
Degenerative polyarthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Human YKL39 (chitinase 3-like protein 2), an osteoarthritis-associated gene, enhances proliferation and type II collagen expression in ATDC5 cells.
|
23291184 |
2013 |
|
Degenerative polyarthritis
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
YKL-39 expression was significantly upregulated in cartilage from patients with osteoarthritis (n=14) versus normal subjects (n=8) according to real-time PCR (19-fold, p=0.009) and cDNA array analysis (mean 15-fold, p<0.001) and correlated with collagen 2 up-regulation.
|
12435396 |
2002 |
|
Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Tissue multi arrays of conventional RCC without metastasis at the time of operation from a cohort of 634 patients were analysed by immunohistochemistry for expression of the chitinase 3-like protein 2 (CHI3L2).
|
31810965 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
M2 Macrophage Marker Chitinase 3-Like 2 (CHI3L2) Associates With Progression of Conventional Renal Cell Carcinoma.
|
31810965 |
2019 |
|
Invasive carcinoma of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of YKL-39 expression in tumors after neoadjuvant chemotherapy (NAC) were predictive for increased risk of distant metastasis and for poor response to NAC in patients with nonspecific invasive breast carcinoma.
|
29872578 |
2018 |
|
Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunization with YKL-39 induced arthritis in all strains of mice tested, among which BALB/c was most susceptible.
|
12102470 |
2003 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The YKL-39-immunised mice produced not only anti-YKL-39 antibody but also antibody against type II collagen, suggesting a spreading of autoimmunity after YKL-39.
|
12102470 |
2003 |
|
Arthropathy
|
0.010 |
Biomarker
|
group |
BEFREE |
YKL-39 and YKL-40 are potentially interesting marker molecules for arthritic joint disease because they are abundantly expressed by both normal and osteoarthritic chondrocytes.
|
12972480 |
2003 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Gene fragments selectively amplified in osteoarthritic cartilage by cDNA representational difference analysis included YKL-39 and the oesophageal-cancer-related-gene-4 (ECRG4).
|
12435396 |
2002 |